New device hunts for wandering cancer cells to predict relapse

NCT ID NCT05360290

Recruiting now Knowledge-focused Sponsor: RenJi Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a device called GILUPI CellCollector® that captures circulating tumor cells (CTCs) from a vein in breast cancer patients who have already completed surgery and chemotherapy. The goal is to see if the presence of these cells can help predict whether the cancer will come back. About 484 women will take part across multiple hospitals, and researchers will track their health for several years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GILUPI CellCollector® (a medical device that captures circulating tumor cells from a vein)
What this could lead to: If successful, this could help doctors better predict which breast cancer patients are at higher risk of their cancer returning after surgery and neoadjuvant treatment.
What could go wrong: This is an observational study, not a treatment trial. The device is already approved, but it is unclear if measuring these cells will actually improve patient outcomes or change how doctors manage care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm invasive breast carcinoma Neoplastic Cells, Circulating

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER CIRCULATING TUMOR CELL

Contacts and locations

Locations

Renji Hospital, School of Medicine, Shanghai Jiao Tong University
RECRUITING

Shanghai, Shanghai Municipality, 200127, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.